Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.
J Infect Dis
; 204(5): 777-82, 2011 Sep 01.
Article
en En
| MEDLINE
| ID: mdl-21844304
ABSTRACT
A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Gripe Humana
/
Subtipo H1N1 del Virus de la Influenza A
/
Zanamivir
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Child, preschool
/
Humans
/
Infant
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
J Infect Dis
Año:
2011
Tipo del documento:
Article
País de afiliación:
Países Bajos